Alan raises €480 million Series G led by Prosus, boosting European health‑tech funding
Executive summary: Alan secured a €480 million Series G funding round led by Prosus. The deal signals strong investor confidence in European health‑tech and adds to record venture funding in the sector.
Who is involved: Alan (health‑tech unicorn), Prosus (lead investor), and existing backers (not named).
Likely next: Proceeds will fund product development, geographic expansion, and potential follow‑on M&A or IPO activity.
Alan, a European health‑tech unicorn, closed a Series G round totaling €480 million, with Prosus acting as lead investor. The round values the company at a multi‑billion‑euro level, though the exact valuation was not disclosed. The investment reflects continued appetite for digital health ventures despite broader market volatility. Prosus’s involvement may bring strategic synergies with its existing consumer‑internet portfolio.
Timeline
- — Health unicorn Alan raises €480m Series G round led by Prosus (Sifted)
Analysis — what this means
Likely next events
- The round may set a new benchmark for European health‑tech valuations
Sectors affected
- Health‑tech
- Digital health
- Venture capital
Regulatory implications
- Increased focus on data‑privacy compliance as Alan scales
Historical parallels
- Babylon Health’s Series F round in 2021
- Kry’s €500 million raise in 2022
- Oscar Health’s $1 billion round in 2020